Treatment options for MDS and AML

The management of AML and MDS often involves a multidimensional approach. The use of targeted therapies, such as flip 3 inhibitors or ideh inhibitors, can be effective, especially in patients with specific molecular mutations. Combination therapies, such as HMAVN or HMAVN with a targeted therapy, show promise in elderly patients. The decision to pursue intensive treatment versus non-intensive treatment depends on factors such as age, comorbidities, and the potential for stem cell transplantation. In certain cases, oral hypomethylating agents, like oral decidobene, could be used for convenience. Maintenance therapy, especially after achieving remission, is being explored as a way to improve outcomes. Lastly, the use of antibody drug conjugates, like C-D123 ADC, shows potential for specific subsets of AML. However, further research is needed to fully understand their efficacy.